Articles from Caranx Medical

Caranx Medical (“Caranx”), a French medical device company specializing in the development of an autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the first clinical use of the TAVIPILOT Soft was successfully carried out in France, at Clinique Pasteur (Toulouse) with Dr. Didier Tchetche and his team, between October 20 and 22, 2025, as part of the SAITO-1A study (First-in-Human trial).

Caranx Medical (“Caranx”, a CarvOlix group company), a French medical device company specializing in the development of an autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, will showcase updates at the 37th Annual Transcatheter Cardiovascular Therapeutics® Conference (TCT) taking place October 25-28, 2005, in San Francisco, California. Caranx will feature the company’s recently FDA-cleared TAVIPILOT software during the TCT Innovation Session #16 “Robotics and AI-Enhanced Interventions” on Tuesday, October 28th at 10:00 AM PT in Innovation Theater Hall E at the Moscone Convention Center. Attendees will also be able to learn more about TAVIPILOT at the Caranx booth (#2252).

Caranx Medical (“Caranx”), a French medical device company specializing in the development of an autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced FDA clearance for US commercialization of the world's first AI Software for real-time intra-operative guidance of transcatheter heart valve implantation.